IP rights have nothing to do with slow global rollout of vaccines
Despite this, some 90 developing nations, led by India and SA, have called for a waiver to suspend all intellectual property rights associated with Covid-19 innovations
In the face of a Covid-19 pandemic that has caused 2.6-million fatalities worldwide, life sciences companies have raced to bring forward a wide range of life-saving innovations, including novel diagnostic tests such as that of LumiraDx, which can detect the virus within minutes; therapeutics, such as Gilead Science’s remdesivir; and highly effective vaccines such as those from Moderna, Pfizer-BioNTech, and Johnson & Johnson.
More than 600 novel Covid-19 treatments are under development, including 130 vaccines in global clinical trials and 176 in pre-clinical trials...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.